Onxeo S.A.: Publication of 2015 Reference Document

PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, Nasdaq Copenhagen:
ONXEO), an innovative company specializing in the development of orphan oncology
therapeutics, announced the publication of the Company’s 2015 Reference
Document.

The 2015 Reference Document, registered with the French Market Authorities
(Autorité des Marchés Financiers) on April 29, 2016, is available to the public
free of charge upon request, as per current legal regulations, at Onxeo’s
headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and on the
Company’s
website: http://www.onxeo.com/en/investisseurs/ (http://cts.businesswire.com/ct/
C 
T?id=smartlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Finvestisseurs%2F&esheet=513
3 
5415&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Finvestisseurs%2F&index=1&md5=976304
2 
350c8a8629a41a48306068629).

The annual financial report, the report of the Chairman of the Board of
Directors on corporate governance and internal control and risk management
procedures as well as the related auditors' reports and information on the fees
paid to the statutory auditors in 2015 are included in this Reference Document.

About Onxeo

Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
comprehensive portfolio features a broad orphan oncology pipeline, with three
independent programs in advanced clinical development, including Onxeo’s first
approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully
developed and registered two non-cancer products which are currently being
commercialized in the U.S. and Europe. Onxeo’s vision is to become a global
leader and pioneer in oncology, with a focus on orphan or rare cancers, by
developing advanced, effective, and safe therapeutics designed to improve the
lives of patients. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker:
ONXEO).

Onxeo orphan oncology products at the advanced development stage are:

  · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
and in combination with other cancer agents in first-line HCC
  · Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the U.S., Spectrum Pharmaceuticals; belinostat in combination with other cancer
agents is currently in development in first-line treatment for patients with
PTCL (BelCHOP) and in other solid tumors
  · AsiDNA : the first-in-class siDNA (signal interfering DNA) which has
successfully undergone a proof-of-concept Phase 1/2a trial in metastatic
melanoma
  · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis;

Learn more by
visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%
3 
A%2F%2Fwww.onxeo.com&esheet=51335415&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=2&md5=2715b71565a2a1146ffe2227e31e1b70).

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51335415&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=3&md5=42865af54
0 
c23cf8fc4662be2c2ecf7d)
Follow us on Twitter: @Onxeo_

Disclaimer

This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2015 Reference
Document filed with the AMF on April 29, 2016, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51335415&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=4&md5=00b49db4286b5ddbcec19c82893ff8b5)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51335415&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=5&md5=fca014ea6113e64dc519ac9ee9f3bec3)).
Investor Relations, Onxeo
Nathalie Delair-Trepo, + 33 1 45 58 76 00
investors@onxeo.com
or
Alize RP (France)
Caroline Carmagnol / Florence Portejoie, +33 6 64 18 99 59 / +33 6 47 38 90 04
onxeo@alizerp.com
or
The Ruth Group (U.S.)
Kirsten Thomas / Lee Roth, +1-508-280-6592 / +1-646-536-7012
kthomas@theruthgroup.com / lroth@theruthgroup.com